Retirement Guys Formula LLC Acquires 210 Shares of Cencora, Inc. (NYSE:COR)

Retirement Guys Formula LLC increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 3.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,192 shares of the company’s stock after purchasing an additional 210 shares during the quarter. Retirement Guys Formula LLC’s holdings in Cencora were worth $1,391,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of COR. Valeo Financial Advisors LLC increased its stake in Cencora by 5.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company’s stock worth $370,000 after purchasing an additional 79 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Cencora by 41.6% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,334 shares of the company’s stock worth $1,201,000 after purchasing an additional 1,568 shares in the last quarter. CX Institutional increased its stake in Cencora by 8.0% during the 3rd quarter. CX Institutional now owns 8,868 shares of the company’s stock worth $1,996,000 after purchasing an additional 654 shares in the last quarter. Occidental Asset Management LLC increased its stake in Cencora by 4.3% during the 3rd quarter. Occidental Asset Management LLC now owns 16,193 shares of the company’s stock worth $3,645,000 after purchasing an additional 665 shares in the last quarter. Finally, NBC Securities Inc. increased its stake in Cencora by 3.9% during the 3rd quarter. NBC Securities Inc. now owns 5,680 shares of the company’s stock worth $1,278,000 after purchasing an additional 211 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock valued at $17,790,912 in the last quarter. 10.80% of the stock is currently owned by insiders.

Cencora Price Performance

NYSE:COR opened at $246.86 on Wednesday. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $262.26. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. The firm has a fifty day simple moving average of $238.86 and a 200 day simple moving average of $237.03. The stock has a market capitalization of $47.71 billion, a PE ratio of 35.11, a P/E/G ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts expect that Cencora, Inc. will post 15.36 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s dividend payout ratio is 31.29%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on COR. Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. UBS Group raised their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Wells Fargo & Company raised their price target on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Finally, Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $277.90.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.